123 related articles for article (PubMed ID: 34694198)
1. A biomarker panel predicts recurrence-free survival in ulcerated primary cutaneous melanoma.
Falkenius J; Keskitalo J; Kanter L; Johansson H; Höiom V; Hansson J; Egyhazi Brage S
Acta Oncol; 2022 Jan; 61(1):14-21. PubMed ID: 34694198
[TBL] [Abstract][Full Text] [Related]
2. Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma.
Falkenius J; Johansson H; Tuominen R; Frostvik Stolt M; Hansson J; Egyhazi Brage S
BMC Cancer; 2017 Aug; 17(1):584. PubMed ID: 28851300
[TBL] [Abstract][Full Text] [Related]
3. Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas.
de Moll EH; Fu Y; Qian Y; Perkins SH; Wieder S; Gnjatic S; Remark R; Bernardo SG; Moskalenko M; Yao J; Ferringer T; Chang R; Chipuk J; Horst BA; Birge MB; Phelps RG; Saenger YM
Cancer Immunol Immunother; 2015 Sep; 64(9):1193-203. PubMed ID: 26076664
[TBL] [Abstract][Full Text] [Related]
4. Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases.
Chatziioannou E; Roßner J; Aung TN; Rimm DL; Niessner H; Keim U; Serna-Higuita LM; Bonzheim I; Kuhn Cuellar L; Westphal D; Steininger J; Meier F; Pop OT; Forchhammer S; Flatz L; Eigentler T; Garbe C; Röcken M; Amaral T; Sinnberg T
EBioMedicine; 2023 Jul; 93():104644. PubMed ID: 37295047
[TBL] [Abstract][Full Text] [Related]
5. Primary tumour ulceration in cutaneous melanoma: its role on TNM stages.
Tas F; Erturk K
Jpn J Clin Oncol; 2021 Feb; 51(2):192-198. PubMed ID: 33159197
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Significance of Incipient Ulceration in Primary Cutaneous Melanoma.
Paver EC; Ahmed T; Burke H; Saw RPM; Stretch JR; Spillane AJ; Shannon KF; Vergara IA; Elder DE; Lo SN; Thompson JF; Scolyer RA
JAMA Dermatol; 2023 Dec; 159(12):1359-1367. PubMed ID: 37910123
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in localized invasive primary cutaneous malignant melanoma: results of a large population-based study.
Eriksson H; Frohm-Nilsson M; Järås J; Kanter-Lewensohn L; Kjellman P; Månsson-Brahme E; Vassilaki I; Hansson J
Br J Dermatol; 2015 Jan; 172(1):175-86. PubMed ID: 24910143
[TBL] [Abstract][Full Text] [Related]
8. Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.
Weiss SA; Han SW; Lui K; Tchack J; Shapiro R; Berman R; Zhong J; Krogsgaard M; Osman I; Darvishian F
Hum Pathol; 2016 Nov; 57():116-125. PubMed ID: 27473267
[TBL] [Abstract][Full Text] [Related]
9. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
Taylor RC; Patel A; Panageas KS; Busam KJ; Brady MS
J Clin Oncol; 2007 Mar; 25(7):869-75. PubMed ID: 17327608
[TBL] [Abstract][Full Text] [Related]
10. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
11. Increased tumour cell PD-L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas.
Koelblinger P; Emberger M; Drach M; Cheng PF; Lang R; Levesque MP; Bauer JW; Dummer R
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):667-675. PubMed ID: 30357969
[TBL] [Abstract][Full Text] [Related]
12. Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations.
Iacono D; Cinausero M; Gerratana L; Angione V; Scott CA; De Maglio G; Pizzolitto S; Di Loreto C; Puglisi F; Fasola G; Minisini AM
Melanoma Res; 2018 Dec; 28(6):547-554. PubMed ID: 29794562
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
[TBL] [Abstract][Full Text] [Related]
14. The proportion cured of patients diagnosed with Stage III-IV cutaneous malignant melanoma in Sweden 1990-2007: A population-based study.
Eriksson H; Lyth J; Andersson TM
Int J Cancer; 2016 Jun; 138(12):2829-36. PubMed ID: 26815934
[TBL] [Abstract][Full Text] [Related]
15. Prognostic risk factors of first recurrence in patients with primary stages I-II cutaneous malignant melanoma - from the population-based Swedish melanoma register.
Lyth J; Falk M; Maroti M; Eriksson H; Ingvar C
J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1468-1474. PubMed ID: 28419674
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling of primary cutaneous melanoma.
Winnepenninckx V; Van den Oord JJ
Verh K Acad Geneeskd Belg; 2007; 69(1):23-45. PubMed ID: 17427873
[TBL] [Abstract][Full Text] [Related]
17. Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?
Eggermont AM; Spatz A; Lazar V; Robert C
Curr Opin Oncol; 2012 Mar; 24(2):137-40. PubMed ID: 22234255
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients.
Ren M; Dai B; Kong YY; Lv JJ; Cai X
Histopathology; 2018 Sep; 73(3):386-396. PubMed ID: 29637587
[TBL] [Abstract][Full Text] [Related]
19. Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients.
Massi D; Romano E; Rulli E; Merelli B; Nassini R; De Logu F; Bieche I; Baroni G; Cattaneo L; Xue G; Mandalà M
Eur J Cancer; 2017 Jun; 78():70-81. PubMed ID: 28412591
[TBL] [Abstract][Full Text] [Related]
20. Population-based analysis of the prevalence of BRAF mutation in patients diagnosed with cutaneous melanoma and its significance as a prognostic factor.
Rubió-Casadevall J; Carbó-Bagué A; Puigdemont M; Osca-Gelis G; Oliveras G; Vilar-Coromina N; Ferrer-Fabrega B; Urban A; Llobet-Roma M; Martín-Romero F; Perez-Bueno F; Marcos-Gragera R
Eur J Dermatol; 2021 Oct; 31(5):616-622. PubMed ID: 34789445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
